Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Rating of “Hold” from Brokerages

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) have received a consensus rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $2.50.

A number of research firms recently commented on HRTX. Wall Street Zen downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research cut shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. Needham & Company LLC cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. HC Wainwright lowered their price objective on shares of Heron Therapeutics to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a report on Tuesday, April 21st.

Heron Therapeutics Price Performance

Shares of NASDAQ HRTX opened at $0.47 on Friday. The company has a quick ratio of 1.51, a current ratio of 2.53 and a debt-to-equity ratio of 17.51. Heron Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $2.04. The business has a 50 day moving average price of $0.57 and a two-hundred day moving average price of $0.93. The firm has a market cap of $89.09 million, a PE ratio of -2.62 and a beta of 1.65.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Monday, May 11th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Heron Therapeutics had a negative net margin of 20.53% and a negative return on equity of 7,747.30%. The business had revenue of $34.71 million during the quarter, compared to analyst estimates of $36.72 million. Sell-side analysts expect that Heron Therapeutics will post -0.09 earnings per share for the current fiscal year.

Institutional Trading of Heron Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of HRTX. Bank of America Corp DE raised its holdings in shares of Heron Therapeutics by 19.7% during the first quarter. Bank of America Corp DE now owns 160,979 shares of the biotechnology company’s stock valued at $129,000 after acquiring an additional 26,534 shares during the period. Excelsior Advisor Network LLC acquired a new position in Heron Therapeutics in the first quarter worth approximately $229,000. Orbimed Advisors LLC acquired a new position in shares of Heron Therapeutics during the 1st quarter worth $7,855,000. Pale Fire Capital SE increased its position in Heron Therapeutics by 84.8% during the first quarter. Pale Fire Capital SE now owns 2,716,328 shares of the biotechnology company’s stock worth $2,173,000 after buying an additional 1,246,673 shares during the last quarter. Finally, HORAN Wealth LLC acquired a new position in shares of Heron Therapeutics during the 1st quarter valued at about $33,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.